Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Neurocognition in Post-Treatment Lyme Disease and Major Depressive Disorder.

Keilp JG, Corbera K, Gorlyn M, Oquendo MA, Mann JJ, Fallon BA.

Arch Clin Neuropsychol. 2019 Jun 1;34(4):466-480. doi: 10.1093/arclin/acy083.

PMID:
30418507
2.

A Community Study of Borrelia burgdorferi Antibodies among Individuals with Prior Lyme Disease in Endemic Areas.

Strobino B, Steinhagen K, Meyer W, Scheper T, Saschenbrecker S, Schlumberger W, Stöcker W, Gaito A, Fallon BA.

Healthcare (Basel). 2018 Jun 19;6(2). pii: E69. doi: 10.3390/healthcare6020069.

3.

C-Reactive Protein Response in Patients With Post-Treatment Lyme Disease Symptoms Versus Those With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Uhde M, Indart A, Fallon BA, Wormser GP, Marques AR, Vernon SD, Alaedini A.

Clin Infect Dis. 2018 Sep 28;67(8):1309-1310. doi: 10.1093/cid/ciy299. No abstract available.

4.

Depressive Symptoms and Suicidal Ideation Among Symptomatic Patients With a History of Lyme Disease vs Two Comparison Groups.

Doshi S, Keilp JG, Strobino B, McElhiney M, Rabkin J, Fallon BA.

Psychosomatics. 2018 Sep - Oct;59(5):481-489. doi: 10.1016/j.psym.2018.02.004. Epub 2018 Mar 1.

5.

The Data as It Is, and the Nature of Neurocognitive Difficulties in Post-Treatment Lyme Disease.

Keilp JG, Fallon BA.

Arch Clin Neuropsychol. 2018 Dec 1;33(8):1083-1085. doi: 10.1093/arclin/acx121. No abstract available.

PMID:
29244055
6.

A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis.

Fallon BA, Ahern DK, Pavlicova M, Slavov I, Skritskya N, Barsky AJ.

Am J Psychiatry. 2017 Aug 1;174(8):756-764. doi: 10.1176/appi.ajp.2017.16020189. Epub 2017 Jun 29.

7.

Avoidance in hypochondriasis.

Doherty-Torstrick ER, Walton KE, Barsky AJ, Fallon BA.

J Psychosom Res. 2016 Oct;89:46-52. doi: 10.1016/j.jpsychores.2016.07.010. Epub 2016 Jul 19.

PMID:
27663110
8.

Cyberchondria: Parsing Health Anxiety From Online Behavior.

Doherty-Torstrick ER, Walton KE, Fallon BA.

Psychosomatics. 2016 Jul-Aug;57(4):390-400. doi: 10.1016/j.psym.2016.02.002. Epub 2016 Feb 4.

9.

The Relationship of Hypochondriasis to Anxiety, Depressive, and Somatoform Disorders.

Scarella TM, Laferton JA, Ahern DK, Fallon BA, Barsky A.

Psychosomatics. 2016 Mar-Apr;57(2):200-7. doi: 10.1016/j.psym.2015.10.006. Epub 2015 Oct 23.

10.

A comparison of lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment.

Fallon BA, Pavlicova M, Coffino SW, Brenner C.

Clin Infect Dis. 2014 Dec 15;59(12):1705-10. doi: 10.1093/cid/ciu703. Epub 2014 Sep 2.

PMID:
25182244
11.

Acute and chronic pain associated with Lyme borreliosis: clinical characteristics and pathophysiologic mechanisms.

Zimering JH, Williams MR, Eiras ME, Fallon BA, Logigian EL, Dworkin RH.

Pain. 2014 Aug;155(8):1435-8. doi: 10.1016/j.pain.2014.04.024. Epub 2014 Apr 24. Review. No abstract available.

PMID:
24769365
12.

Ongoing discussion about the US clinical Lyme trials.

Fallon BA, Petkova E, Keilp JG, Britton CB.

Am J Med. 2014 Feb;127(2):e7. doi: 10.1016/j.amjmed.2013.09.005. No abstract available.

PMID:
24462018
13.

Modulation of motor cortex excitability in obsessive-compulsive disorder: an exploratory study on the relations of neurophysiology measures with clinical outcome.

Mantovani A, Rossi S, Bassi BD, Simpson HB, Fallon BA, Lisanby SH.

Psychiatry Res. 2013 Dec 30;210(3):1026-32. doi: 10.1016/j.psychres.2013.08.054. Epub 2013 Sep 21.

PMID:
24064461
14.

Distinct neural circuits subserve interpersonal and non-interpersonal emotions.

Landa A, Wang Z, Russell JA, Posner J, Duan Y, Kangarlu A, Huo Y, Fallon BA, Peterson BS.

Soc Neurosci. 2013;8(5):474-88. doi: 10.1080/17470919.2013.833984.

15.

Post-treatment lyme syndrome and central sensitization.

Batheja S, Nields JA, Landa A, Fallon BA.

J Neuropsychiatry Clin Neurosci. 2013 Summer;25(3):176-86. doi: 10.1176/appi.neuropsych.12090223. Review.

PMID:
24026711
16.

Correlates of perceived health-related quality of life in post-treatment Lyme encephalopathy.

Chandra AM, Keilp JG, Fallon BA.

Psychosomatics. 2013 Nov-Dec;54(6):552-9. doi: 10.1016/j.psym.2013.04.003. Epub 2013 Jul 9.

17.

Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits.

Jacek E, Fallon BA, Chandra A, Crow MK, Wormser GP, Alaedini A.

J Neuroimmunol. 2013 Feb 15;255(1-2):85-91. doi: 10.1016/j.jneuroim.2012.10.011. Epub 2012 Nov 8.

18.

A reappraisal of the u.s. Clinical trials of post-treatment lyme disease syndrome.

Fallon BA, Petkova E, Keilp JG, Britton CB.

Open Neurol J. 2012;6:79-87. doi: 10.2174/1874205X01206010079. Epub 2012 Oct 5.

19.

Somatoform pain: a developmental theory and translational research review.

Landa A, Peterson BS, Fallon BA.

Psychosom Med. 2012 Sep;74(7):717-27. doi: 10.1097/PSY.0b013e3182688e8b. Epub 2012 Aug 28. Review.

20.

Personality disorders in hypochondriasis: prevalence and comparison with two anxiety disorders.

Fallon BA, Harper KM, Landa A, Pavlicova M, Schneier FR, Carson A, Harding K, Keegan K, Schwartz T, Liebowitz MR.

Psychosomatics. 2012 Nov-Dec;53(6):566-74. doi: 10.1016/j.psym.2012.02.002. Epub 2012 May 31.

21.

A clinician-administered severity rating scale for illness anxiety: development, reliability, and validity of the H-YBOCS-M.

Skritskaya NA, Carson-Wong AR, Moeller JR, Shen S, Barsky AJ, Fallon BA.

Depress Anxiety. 2012 Jul;29(7):652-64. doi: 10.1002/da.21949. Epub 2012 Apr 13.

22.

Long-term follow-up of hypochondriasis after selective serotonin reuptake inhibitor treatment.

Schweitzer PJ, Zafar U, Pavlicova M, Fallon BA.

J Clin Psychopharmacol. 2011 Jun;31(3):365-8. doi: 10.1097/JCP.0b013e31821896c3.

PMID:
21508861
23.

Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome.

Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH.

PLoS One. 2011 Feb 23;6(2):e17287. doi: 10.1371/journal.pone.0017287.

24.

PET tracers for the peripheral benzodiazepine receptor and uses thereof.

Schweitzer PJ, Fallon BA, Mann JJ, Kumar JS.

Drug Discov Today. 2010 Nov;15(21-22):933-42. doi: 10.1016/j.drudis.2010.08.012. Epub 2010 Aug 26. Review.

PMID:
20800696
25.

Body dysmorphic disorder: some key issues for DSM-V.

Phillips KA, Wilhelm S, Koran LM, Didie ER, Fallon BA, Feusner J, Stein DJ.

Depress Anxiety. 2010 Jun;27(6):573-91. doi: 10.1002/da.20709. Review.

26.

Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Phillips KA, Stein DJ, Rauch SL, Hollander E, Fallon BA, Barsky A, Fineberg N, Mataix-Cols D, Ferrão YA, Saxena S, Wilhelm S, Kelly MM, Clark LA, Pinto A, Bienvenu OJ, Farrow J, Leckman J.

Depress Anxiety. 2010 Jun;27(6):528-55. doi: 10.1002/da.20705. Review.

27.

Inflammation and central nervous system Lyme disease.

Fallon BA, Levin ES, Schweitzer PJ, Hardesty D.

Neurobiol Dis. 2010 Mar;37(3):534-41. doi: 10.1016/j.nbd.2009.11.016. Epub 2009 Nov 26. Review.

PMID:
19944760
28.

Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder.

Mantovani A, Simpson HB, Fallon BA, Rossi S, Lisanby SH.

Int J Neuropsychopharmacol. 2010 Mar;13(2):217-27. doi: 10.1017/S1461145709990435. Epub 2009 Aug 20.

PMID:
19691873
29.

Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy.

Fallon BA, Lipkin RB, Corbera KM, Yu S, Nobler MS, Keilp JG, Petkova E, Lisanby SH, Moeller JR, Slavov I, Van Heertum R, Mensh BD, Sackeim HA.

Arch Gen Psychiatry. 2009 May;66(5):554-63. doi: 10.1001/archgenpsychiatry.2009.29.

PMID:
19414715
30.

Long-term follow-up study of patients with refractory obsessive-compulsive disorder.

Ross S, Fallon BA, Petkova E, Feinstein S, Liebowitz MR.

J Neuropsychiatry Clin Neurosci. 2008 Fall;20(4):450-7. doi: 10.1176/appi.neuropsych.20.4.450.

PMID:
19196930
31.

A double-masked, placebo-controlled study of fluoxetine for hypochondriasis.

Fallon BA, Petkova E, Skritskaya N, Sanchez-Lacay A, Schneier F, Vermes D, Cheng J, Liebowitz MR.

J Clin Psychopharmacol. 2008 Dec;28(6):638-45. doi: 10.1097/JCP.0b013e31818d21cf.

PMID:
19011432
32.

Advances in understanding illness anxiety.

Harding KJ, Skritskaya N, Doherty E, Fallon BA.

Curr Psychiatry Rep. 2008 Aug;10(4):311-7. Review.

PMID:
18627669
33.

A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy.

Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA.

Neurology. 2008 Mar 25;70(13):992-1003. Epub 2007 Oct 10.

PMID:
17928580
34.

Lyme disease associated with Alzheimer's disease.

Meer-Scherrer L, Chang Loa C, Adelson ME, Mordechai E, Lobrinus JA, Fallon BA, Tilton RC.

Curr Microbiol. 2006 Apr;52(4):330-2. Epub 2006 Mar 9.

PMID:
16528463
35.

WAIS-III and WMS-III performance in chronic Lyme disease.

Keilp JG, Corbera K, Slavov I, Taylor MJ, Sackeim HA, Fallon BA.

J Int Neuropsychol Soc. 2006 Jan;12(1):119-29.

PMID:
16433951
36.

Biological therapies for obsessive-compulsive disorder.

Fallon BA, Mathew SJ.

J Psychiatr Pract. 2000 May;6(3):113-28.

PMID:
15990479
37.

Obsessive-compulsive disorder: an overview.

Simpson HB, Fallon BA.

J Psychiatr Pract. 2000 Jan;6(1):3-17.

PMID:
15990471
38.

Pharmacotherapy of somatoform disorders.

Fallon BA.

J Psychosom Res. 2004 Apr;56(4):455-60. Review.

PMID:
15094032
39.

Regional cerebral blood flow and cognitive deficits in chronic lyme disease.

Fallon BA, Keilp J, Prohovnik I, Heertum RV, Mann JJ.

J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):326-32.

PMID:
12928508
40.

An open trial of fluvoxamine for hypochondriasis.

Fallon BA, Qureshi AI, Schneier FR, Sanchez-Lacay A, Vermes D, Feinstein R, Connelly J, Liebowitz MR.

Psychosomatics. 2003 Jul-Aug;44(4):298-303.

PMID:
12832595
41.

Item-by-item factor analysis of the Yale-Brown Obsessive Compulsive Scale Symptom Checklist.

Feinstein SB, Fallon BA, Petkova E, Liebowitz MR.

J Neuropsychiatry Clin Neurosci. 2003 Spring;15(2):187-93.

PMID:
12724460
42.

Canadian Incidence Study of Reported Child Abuse and Neglect: methodology.

Trocmé NM, MacLaurin BJ, Fallon BA, Daciuk JF, Tourigny M, Billingsley DA.

Can J Public Health. 2001 Jul-Aug;92(4):259-63.

PMID:
11962109
43.

Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder.

Mathew SJ, Coplan JD, Perko KA, Goetz RR, de la Neuz M, Hollander E, Liebowitz MR, Fallon BA.

Depress Anxiety. 2001;14(4):199-208.

PMID:
11754126
44.

A controlled study of cognitive deficits in children with chronic Lyme disease.

Tager FA, Fallon BA, Keilp J, Rissenberg M, Jones CR, Liebowitz MR.

J Neuropsychiatry Clin Neurosci. 2001 Fall;13(4):500-7.

PMID:
11748319
45.

Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.

Kochan LD, Qureshi AI, Fallon BA.

Curr Psychiatry Rep. 2000 Aug;2(4):327-34. Review.

PMID:
11122977
46.

Hypochondriasis and its relationship to obsessive-compulsive disorder.

Fallon BA, Qureshi AI, Laje G, Klein B.

Psychiatr Clin North Am. 2000 Sep;23(3):605-16. Review.

PMID:
10986730
47.

Carbamazepine in the treatment of Lyme disease-induced hyperacusis.

Nields JA, Fallon BA, Jastreboff PJ.

J Neuropsychiatry Clin Neurosci. 1999 Winter;11(1):97-9.

PMID:
9990563
48.

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF.

Arch Gen Psychiatry. 1998 Oct;55(10):918-24.

PMID:
9783563
49.

The underdiagnosis of neuropsychiatric Lyme disease in children and adults.

Fallon BA, Kochevar JM, Gaito A, Nields JA.

Psychiatr Clin North Am. 1998 Sep;21(3):693-703, viii. Review.

PMID:
9774805
50.

Acute disseminated encephalomyelitis.

Fallon BA, Nields JA.

J Neuropsychiatry Clin Neurosci. 1998 Summer;10(3):366-7. No abstract available.

PMID:
9706548

Supplemental Content

Loading ...
Support Center